Agenus bags cancer antibodies in $44M deal

Lexington, MA-based Agenus has bagged the rights to some cancer-related antibodies from Italy's Diatheva s.r.l., agreeing to fork over up to $44 million in milestones for a successful development program. These antibodies target carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes. CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been studied in preclinical work which has illustrated an ability to "modulate innate and adaptive immune suppression." Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.